SG11201811712QA - 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases - Google Patents
5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseasesInfo
- Publication number
- SG11201811712QA SG11201811712QA SG11201811712QA SG11201811712QA SG11201811712QA SG 11201811712Q A SG11201811712Q A SG 11201811712QA SG 11201811712Q A SG11201811712Q A SG 11201811712QA SG 11201811712Q A SG11201811712Q A SG 11201811712QA SG 11201811712Q A SG11201811712Q A SG 11201811712QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- street
- pct
- applicant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357624P | 2016-07-01 | 2016-07-01 | |
US201662372421P | 2016-08-09 | 2016-08-09 | |
PCT/IB2017/053565 WO2018002760A1 (en) | 2016-07-01 | 2017-06-15 | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811712QA true SG11201811712QA (en) | 2019-01-30 |
Family
ID=59215839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811712QA SG11201811712QA (en) | 2016-07-01 | 2017-06-15 | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
Country Status (21)
Country | Link |
---|---|
US (5) | US10604519B2 (pl) |
EP (2) | EP3872078A1 (pl) |
JP (1) | JP7046018B2 (pl) |
KR (1) | KR102470497B1 (pl) |
CN (1) | CN109641898B (pl) |
AU (1) | AU2017286868B2 (pl) |
BR (1) | BR112018077257A2 (pl) |
CA (1) | CA2972070A1 (pl) |
DK (1) | DK3478679T3 (pl) |
ES (1) | ES2878160T3 (pl) |
HU (1) | HUE054857T2 (pl) |
IL (1) | IL263912B (pl) |
MX (1) | MX2019000231A (pl) |
PH (1) | PH12019500004A1 (pl) |
PL (1) | PL3478679T3 (pl) |
PT (1) | PT3478679T (pl) |
SG (1) | SG11201811712QA (pl) |
TW (1) | TWI736642B (pl) |
UY (1) | UY37311A (pl) |
WO (1) | WO2018002760A1 (pl) |
ZA (1) | ZA201900519B (pl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3634408B1 (en) | 2017-06-09 | 2022-12-28 | Merck Sharp & Dohme LLC | Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor |
PL3642202T3 (pl) * | 2017-06-22 | 2023-03-13 | Pfizer Inc. | Pochodne dihydropirolopirydyny |
CN114728964A (zh) | 2019-11-22 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 吡咯烷衍生物 |
CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
WO2022235514A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Liposome delivery of psychedelics |
WO2024061253A1 (zh) * | 2022-09-23 | 2024-03-28 | 苏州科睿思制药有限公司 | Emraclidine的晶型及其制备方法和用途 |
WO2024088408A1 (zh) * | 2022-10-28 | 2024-05-02 | 纽欧申医药(上海)有限公司 | 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用 |
WO2024130065A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions |
WO2024130062A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions |
WO2024130064A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions |
WO2024130068A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo [3, 4-d] pyrimidine compounds and their use in treating medical conditions |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017197A1 (en) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTIBODY AGAINST β-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
EP0994728B1 (en) | 1997-04-09 | 2008-07-30 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
DE60106394T3 (de) | 2000-02-24 | 2013-07-25 | Washington University St. Louis | Humanisierte antikörper, die amyloid beta peptid sequestrieren |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
AU3976402A (en) | 2000-11-03 | 2002-06-03 | Proteotech Inc | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
KR20050071564A (ko) | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물 |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
WO2004110996A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
JP2007519707A (ja) | 2004-02-02 | 2007-07-19 | ファイザー・プロダクツ・インク | ヒスタミン−3受容体モジュレーター |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
KR101068289B1 (ko) | 2004-07-30 | 2011-09-28 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법 |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
PL1807434T3 (pl) | 2004-10-25 | 2011-02-28 | Lilly Co Eli | Tienopirydyny jako allosteryczne środki wzmacniające receptor M4 muskarynowy |
WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
ATE493413T1 (de) | 2005-05-12 | 2011-01-15 | Pfizer | Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- |
WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
ATE488496T1 (de) | 2005-06-22 | 2010-12-15 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
TW200713011A (en) | 2005-09-30 | 2007-04-01 | Hon Hai Prec Ind Co Ltd | System, method and electrical apparatus for data transferring |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
WO2007052124A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
EP2007749A2 (en) | 2006-03-13 | 2008-12-31 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
ES2366239T3 (es) | 2006-04-21 | 2011-10-18 | Pfizer Products Inc. | Piridin[3,4-b]pirazinonas. |
WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
CN1869036A (zh) * | 2006-06-30 | 2006-11-29 | 中国药科大学 | 7-取代-3-氯吡咯并[3,4-b]吡啶化合物 |
DK2124933T3 (da) | 2007-01-22 | 2012-11-19 | Pfizer Prod Inc | Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf |
WO2012047702A1 (en) | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
US9302989B2 (en) * | 2010-11-15 | 2016-04-05 | Abbvie Inc. | NAMPT and rock inhibitors |
AU2012240122B2 (en) * | 2011-04-08 | 2016-08-25 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
JP6240063B2 (ja) * | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート, インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
JP6101279B2 (ja) * | 2011-11-15 | 2017-03-22 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Gpr119アゴニストとして有用な置換シクロプロピル化合物 |
US8741892B2 (en) * | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) * | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
ES2656972T3 (es) | 2012-02-23 | 2018-03-01 | Vanderbilt University | Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4 |
WO2014035829A1 (en) | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
WO2015027214A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
WO2015027204A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
US11497586B2 (en) | 2014-03-21 | 2022-11-15 | Align Technology, Inc. | Segmented orthodontic appliance with elastics |
JP6479029B2 (ja) * | 2014-02-06 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | ムスカリンm1受容体アゴニストとしての二環式アザ化合物 |
-
2017
- 2017-06-15 AU AU2017286868A patent/AU2017286868B2/en active Active
- 2017-06-15 WO PCT/IB2017/053565 patent/WO2018002760A1/en unknown
- 2017-06-15 ES ES17733044T patent/ES2878160T3/es active Active
- 2017-06-15 EP EP21167379.3A patent/EP3872078A1/en active Pending
- 2017-06-15 SG SG11201811712QA patent/SG11201811712QA/en unknown
- 2017-06-15 KR KR1020197002851A patent/KR102470497B1/ko active IP Right Grant
- 2017-06-15 HU HUE17733044A patent/HUE054857T2/hu unknown
- 2017-06-15 PT PT177330446T patent/PT3478679T/pt unknown
- 2017-06-15 EP EP17733044.6A patent/EP3478679B1/en active Active
- 2017-06-15 BR BR112018077257-7A patent/BR112018077257A2/pt active Search and Examination
- 2017-06-15 PL PL17733044T patent/PL3478679T3/pl unknown
- 2017-06-15 CN CN201780053245.2A patent/CN109641898B/zh active Active
- 2017-06-15 JP JP2018568716A patent/JP7046018B2/ja active Active
- 2017-06-15 MX MX2019000231A patent/MX2019000231A/es unknown
- 2017-06-15 DK DK17733044.6T patent/DK3478679T3/da active
- 2017-06-28 CA CA2972070A patent/CA2972070A1/en active Pending
- 2017-06-28 TW TW106121650A patent/TWI736642B/zh active
- 2017-06-29 US US15/637,071 patent/US10604519B2/en active Active
- 2017-06-30 UY UY0001037311A patent/UY37311A/es not_active Application Discontinuation
-
2018
- 2018-12-23 IL IL263912A patent/IL263912B/en unknown
-
2019
- 2019-01-03 PH PH12019500004A patent/PH12019500004A1/en unknown
- 2019-01-24 ZA ZA2019/00519A patent/ZA201900519B/en unknown
-
2020
- 2020-02-21 US US16/797,966 patent/US20200207762A1/en not_active Abandoned
-
2021
- 2021-06-01 US US17/335,666 patent/US11905284B2/en active Active
-
2023
- 2023-02-21 US US18/112,156 patent/US20230192690A1/en active Pending
- 2023-12-07 US US18/532,547 patent/US20240190869A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201901937WA (en) | Pyridine compound | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201906417RA (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |